+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Monoclonal Antibody Therapeutics Market Research Report by Source (Chimeric, Human, and Humanized), End User, Application, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 4829819
  • Report
  • April 2022
  • Region: Global
  • 190 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • AbbVie Inc.
  • Bayer AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Novartis International AG
The Global Monoclonal Antibody Therapeutics Market size was estimated at USD 125.84 billion in 2021, USD 141.33 billion in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 12.48% to reach USD 254.96 billion by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Monoclonal Antibody Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Source, the market was studied across Chimeric, Human, and Humanized.
  • Based on End User, the market was studied across Hospitals, Private Clinics, and Research Institute.
  • Based on Application, the market was studied across Autoimmune Diseases, Cancer, Hematological Diseases, Infectious Diseases, and Ophthalmological Diseases.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.

This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Monoclonal Antibody Therapeutics market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Monoclonal Antibody Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Monoclonal Antibody Therapeutics Market, including AbbVie Inc., Amgen Inc., Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Envigo, F. Hoffmann-La Roche Ltd, GenScript, GlaxoSmithKline Plc, Johnson & Johnson, Merck Sharp & Dohme Corp.,, Novartis International AG, Pfizer Inc, and Sanofi S.A.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Monoclonal Antibody Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Monoclonal Antibody Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Monoclonal Antibody Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global Monoclonal Antibody Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global Monoclonal Antibody Therapeutics Market?
6. What is the market share of the leading vendors in the Global Monoclonal Antibody Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the Global Monoclonal Antibody Therapeutics Market?
Frequently Asked Questions about the Global Monoclonal Antibody Therapeutics Market

What is the estimated value of the Global Monoclonal Antibody Therapeutics Market?

The Global Monoclonal Antibody Therapeutics Market was estimated to be valued at $125.8 Billion in 2021.

What is the growth rate of the Global Monoclonal Antibody Therapeutics Market?

The growth rate of the Global Monoclonal Antibody Therapeutics Market is 12.4%, with an estimated value of $255.0 Billion by 2027.

What is the forecasted size of the Global Monoclonal Antibody Therapeutics Market?

The Global Monoclonal Antibody Therapeutics Market is estimated to be worth $255.0 Billion by 2027.

Who are the key companies in the Global Monoclonal Antibody Therapeutics Market?

Key companies in the Global Monoclonal Antibody Therapeutics Market include AbbVie Inc., Amgen Inc., Bayer AG, Biogen Inc., Bristol, Myers Squibb Company, Eli Lilly and Company, Envigo and La Roche Ltd.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • Bayer AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Novartis International AG

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing adoption of monoclonal antibody therapeutics in cancer treatments
5.1.1.2. Increasing approvals of monoclonal antibodies
5.1.1.3. Rising use of monoclonal antibodies for the treatment of autoimmune diseases
5.1.2. Restraints
5.1.2.1. High cost of clinical research and development
5.1.3. Opportunities
5.1.3.1. Increasing product launches and regulatory support for the treatment of rare diseases
5.1.3.2. Increasing investment in R&D
5.1.4. Challenges
5.1.4.1. Variation in results from patient to patient
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of 2022 Russia Ukraine Conflict
6. Monoclonal Antibody Therapeutics Market, by Source
6.1. Introduction
6.2. Chimeric
6.3. Human
6.4. Humanized
7. Monoclonal Antibody Therapeutics Market, by End User
7.1. Introduction
7.2. Hospitals
7.3. Private Clinics
7.4. Research Institute
8. Monoclonal Antibody Therapeutics Market, by Application
8.1. Introduction
8.2. Autoimmune Diseases
8.3. Cancer
8.4. Hematological Diseases
8.5. Infectious Diseases
8.6. Ophthalmological Diseases
9. Americas Monoclonal Antibody Therapeutics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Monoclonal Antibody Therapeutics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
11. Europe, Middle East & Africa Monoclonal Antibody Therapeutics Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. AbbVie Inc.
13.2. Amgen Inc.
13.3. Bayer AG
13.4. Biogen Inc.
13.5. Bristol-Myers Squibb Company
13.6. Eli Lilly and Company
13.7. Envigo
13.8. F. Hoffmann-La Roche Ltd
13.9. GenScript
13.10. GlaxoSmithKline Plc
13.11. Johnson & Johnson
13.12. Merck Sharp & Dohme Corp.,
13.13. Novartis International AG
13.14. Pfizer Inc
13.15. Sanofi S.A
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DYNAMICS
FIGURE 2. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2021 VS 2027 (%)
FIGURE 3. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2021 VS 2027 (USD BILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2027
FIGURE 5. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, 2019-2027 (USD BILLION)
FIGURE 6. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 7. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, 2019-2027 (USD BILLION)
FIGURE 8. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 9. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, 2019-2027 (USD BILLION)
FIGURE 10. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 11. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2021 VS 2027 (%)
FIGURE 12. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2021 VS 2027 (USD BILLION)
FIGURE 13. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2027
FIGURE 14. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2019-2027 (USD BILLION)
FIGURE 15. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 16. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRIVATE CLINICS, 2019-2027 (USD BILLION)
FIGURE 17. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 18. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTE, 2019-2027 (USD BILLION)
FIGURE 19. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 20. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (%)
FIGURE 21. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (USD BILLION)
FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2027
FIGURE 23. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2019-2027 (USD BILLION)
FIGURE 24. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 25. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CANCER, 2019-2027 (USD BILLION)
FIGURE 26. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CANCER, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 27. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL DISEASES, 2019-2027 (USD BILLION)
FIGURE 28. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL DISEASES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 29. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2019-2027 (USD BILLION)
FIGURE 30. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 31. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGICAL DISEASES, 2019-2027 (USD BILLION)
FIGURE 32. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGICAL DISEASES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 33. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 34. ARGENTINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 35. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 36. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 37. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 38. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 39. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 40. AUSTRALIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 41. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 42. INDIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 43. INDONESIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 44. JAPAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 45. MALAYSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 46. PHILIPPINES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 47. SINGAPORE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 48. SOUTH KOREA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 49. TAIWAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 50. THAILAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 51. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 52. FRANCE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 53. GERMANY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 54. ITALY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 55. NETHERLANDS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 56. QATAR MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 57. RUSSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 58. SAUDI ARABIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 59. SOUTH AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 60. SPAIN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 61. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 62. UNITED KINGDOM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 63. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET: FPNV POSITIONING MATRIX
FIGURE 64. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 65. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2019-2027 (USD BILLION)
TABLE 4. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2019-2027 (USD BILLION)
TABLE 5. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 6. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY STATE, 2019-2027 (USD BILLION)
TABLE 7. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 8. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 9. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY REGION, 2019-2027 (USD BILLION)
TABLE 10. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 11. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY STATE, 2019-2027 (USD BILLION)
TABLE 12. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 13. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 14. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2019-2027 (USD BILLION)
TABLE 15. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 16. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY STATE, 2019-2027 (USD BILLION)
TABLE 17. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 18. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 19. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2019-2027 (USD BILLION)
TABLE 20. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2019-2027 (USD BILLION)
TABLE 21. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 22. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY STATE, 2019-2027 (USD BILLION)
TABLE 23. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 24. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 25. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2019-2027 (USD BILLION)
TABLE 26. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 27. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRIVATE CLINICS, BY STATE, 2019-2027 (USD BILLION)
TABLE 28. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 29. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 30. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2019-2027 (USD BILLION)
TABLE 31. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 32. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTE, BY STATE, 2019-2027 (USD BILLION)
TABLE 33. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 34. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 35. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 36. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2019-2027 (USD BILLION)
TABLE 37. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 38. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY STATE, 2019-2027 (USD BILLION)
TABLE 39. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 40. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 41. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CANCER, BY REGION, 2019-2027 (USD BILLION)
TABLE 42. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 43. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CANCER, BY STATE, 2019-2027 (USD BILLION)
TABLE 44. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 45. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CANCER, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 46. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL DISEASES, BY REGION, 2019-2027 (USD BILLION)
TABLE 47. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 48. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL DISEASES, BY STATE, 2019-2027 (USD BILLION)
TABLE 49. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 50. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 51. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2019-2027 (USD BILLION)
TABLE 52. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 53. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY STATE, 2019-2027 (USD BILLION)
TABLE 54. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 56. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGICAL DISEASES, BY REGION, 2019-2027 (USD BILLION)
TABLE 57. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGICAL DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 58. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGICAL DISEASES, BY STATE, 2019-2027 (USD BILLION)
TABLE 59. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGICAL DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGICAL DISEASES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 61. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 62. ARGENTINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 63. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 64. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 65. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 66. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 67. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 68. AUSTRALIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 69. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 70. INDIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 71. INDONESIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 72. JAPAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 73. MALAYSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 74. PHILIPPINES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 75. SINGAPORE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 76. SOUTH KOREA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 77. TAIWAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 78. THAILAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 80. FRANCE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 81. GERMANY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 82. ITALY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 83. NETHERLANDS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 84. QATAR MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 85. RUSSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 86. SAUDI ARABIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 87. SOUTH AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 88. SPAIN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 89. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 90. UNITED KINGDOM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 91. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET: SCORES
TABLE 92. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET: BUSINESS STRATEGY
TABLE 93. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET: PRODUCT SATISFACTION
TABLE 94. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET: RANKING
TABLE 95. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 96. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET: MERGER & ACQUISITION
TABLE 97. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 98. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 99. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET: INVESTMENT & FUNDING
TABLE 100. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 101. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • AbbVie Inc.
  • Amgen Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Envigo
  • F. Hoffmann-La Roche Ltd
  • GenScript
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck Sharp & Dohme Corp.,
  • Novartis International AG
  • Pfizer Inc
  • Sanofi S.A
Note: Product cover images may vary from those shown

Loading
LOADING...